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Abstract
Immunotherapy	with	immune	checkpoint	inhibitors	(ICIs)	revolutionized	therapy	of	solid	tumors,	among	them-	lung	cancer.	PD-1,	
PD-L1	blockers	have	been	shown	to	improve	overall	survival	in	advanced,	metastatic	non-small	cell	 lung	cancer.	In	individual	
patients,	3-5-year	survival	has	been	achieved.	Nivolumab,	pembrolizumab,	atezolizumab	are	approved	in	lung	cancer	treatment.	
Practical	observations	in	reallife	show	that	the	results	are	comparable	with	those	achieved	in	clinical	trials.	The	effects	of	ICIs	
depend	on	the	patient	performance	status;	age,	sex,	histology;	the	presence	of	brain	metastases	have	not	modified	treatment	
results.	ICIs	therapy	is	safe	and	well	tolerated;	immune	related	adverse	events	are	observed.	Pneumonitis	may	be	a serious	and	
fatal	complication,	but	glucocorticoids	are	usually	curative.	For	proper	patients	selection	for	ICIs	treatment,	the	detection	of	PD-L1	
expression	on	cancer	cells	is	used.	The	so-called	“hot”	tumors	with	high	expression	of	PD-L1	and	abundant	infiltration	by	cytotoxic	
cells	seem	to	better	respond	to	treatment	than	“cold”	tumors.	
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Introduction
Four years ago we paved a new direction in 
lung cancer treatment in this Journal [1]. There-
after immunotherapy with checkpoint inhibitors 
in lung cancer became a  fact. As about 70% of 
non-small cell lung cancers at the moment of 
recognition are in advanced stages of the dise-
ase, immunotherapy with checkpoint inhibitors 
may be a better chance than chemotherapy for 
patients at advanced stage of cancer. The new 
WHO 2015 histological classification is adjusted 
to the newest most effective treatment regiments. 
The methods of the classification allow to distin-
guish the main types of NSCLC with high accu-
racy (Table 1) [2]. Whereas the latest 8th clinical 
categorization reflects important progress in the 
methods of precise evaluation of primary tumor, 
tumor spread and metastases [3]. 
Furthermore, the precise molecular biology 
methods help in the proper selection of patients 
for a targeted therapy with tyrosine kinase inhi-
bitors (IKT) [4]. On the grounds of the accurate 
diagnosis with an individual cancer characteri-
stic, the immunotherapy raises the new hopes 
for patients and seems to significantly change 
the perspectives in lung cancer. The aim of this 
short review is to present the current reports of 
the use of checkpoint blockers in daily clinical 
practice beyond the conditions of clinical trials. 
From clinical trials
Natural anticancer defence in the host orga-
nism is known as immunosurveillance, in which 
the cytotoxic reaction directed to the cancer cells 
is capable of inducing their apoptosis and death. 
The main cytotoxic cells are CD8+ lymphocytes. 
Natural killer cells (NK), natural killer T cells 
(NKT), CD4+ lymphocytes complement this cy-
totoxic cell population. An anticancer reaction 
in the tumor environment (TME) is supported by 
Th1 cytokines (IL-2, INF-g, TNF-a) and M1 ma-
crophages. However, the mechanisms of suppres-
sion and regulation of immune response cause 
the escape of cancer from immunosurveillance 
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along with cancer development. This process is 
complex and it includes the participation of many 
regulatory cells and mediators. The suppressive 
molecules, which are overexpressed on/in lym-
phocytes in the cancer milieu, play a role in im-
munosuppression [1, 5–7]. The issue of suppres-
sive molecule function is to form an inhibitory 
pathway by connection with the corresponding 
ligand on a cancer cell. Such a pathway avoids 
the activation of cytotoxic effector lymphocyte 
and causes its anergy and immunosuppression. 
A classic example of the inhibitory signalling 
pathway is the programmed death-1 (PD-1)/pro-
grammed death- ligand 1 (PD-L1) pathway. 
PD-1 molecule and its inhibitory function 
was discovered by Ishida and Honjo in the 90’s of 
the twentieth century. PD-1 receptor is expressed 
on T cells, B-cells, NK-cells and regulatory T cells. 
In our studies, we found a higher expression of 
PD-1 on memory and activated T cells than on 
naïve cells in lung cancer TME on the basis of 
bronchoalveolar lavage fluid (BALF) examination. 
The proportion of PD-1 positive cells was higher 
in the BALF from the lung affected by cancer than 
in the opposite, “healthy” lung and from periphe-
ral blood (I. Kwiecien, ERS Congress, 2017). The 
ligands to PD-1: PD-L1, PD-L2 are expressed on 
malignant tumor cells, antigen presenting cells 
and other immune cells. The overexpression of 
PD-1 on lymphocytes and PD-L1, 2 on cancer cells 
is observed in many malignancies, and in lung 
cancer as well. The suppressory molecules are 
known as “checkpoints”. The nature of curren-
tly applied cancer immunotherapy is inhibition, 
blockade of these checkpoints by so -called “im-
mune checkpoints inhibitors“ (ICIs). ICIs were 
approved to date in melanoma, squamous cell 
carcinoma of the head and neck, Hodgkin lym-
phoma, kidney carcinoma, Merkel cell carcinoma, 
colon and ventricular carcinoma [8]. 
Anti-PD-1 inhibitors: nivolumab and pem-
brolizumab, anti PD-L1 inhibitor- atezolizu-
mab are approved in non-small cell lung cancer 
(NSCLC) therapy. In clinical trials: Check Mate 
017, Check Mate 057, Keynote 010 and OAK, re-
spectively, these agents have shown improvement 
of overall survival when compared with docetaxel 
chemotherapy in second line therapy of advanced 
NSCLC [9, 10]. In the first line setting, the pem-
brolizumab was shown to improve the response, 
while nivolumab was not. Anti-PD-L1 antibody 
durvalumab in the ATLANTIC and PACIFIC stu-
dies in third line setting was more effective than 
docetaxel. To date the only predictive factor for 
ICIs in lung cancer is the expression of PD-L1 on 
tumor cells. A threshold for PD-L1 expression in 
trials was defined as: 1–5–10% PD-L1 positive 
cancer cells. At least 50% of them were shown 
to be predictive of pembrolizumab when com-
pared with docetaxel in the first line setting of 
treatment. In the OAK study with atezolizumab, 
PD-L1 expression on the tumor cells and also on 
immune cells was taken into account. In spite 
of the fact that in the majority of studies PD-L1 
expression was assessed, the methodological 
discussion concerning immunohistochemical 
detection of PD-L1 has not ended [9, 11]. 
After trials
One could say that ICIs revolutionized advan-
ced lung cancer therapy. The most striking is 
an achievement of prolonged survival of some 
patients with advanced, metastatic disease. In 
clinical trials (CheckMate, Keynote, OAK), the 
median overall survival (OS) was prolonged from 
9.2 to 13.8 months [10]. Taking into account the 
results of clinical studies, immunotherapy has 
recently been introduced in the first line and se-
cond line setting in advanced NSCLC, as presen-
ted in Figure 1. Nivolumab and pembrolizumab 
are humanized anti PD-1 antibodies class IgG4. 
Pembrolizumab could be used in the first line of 
treatment, in NSCLC patients with PD-L1 expres-
sion on more than 50% of tumor cells. However, 
pembrolizumab in second line treatment is used 
in patients with any expression of PD-L1 on tumor 
Table 1.  Accurate histological diagnosis is crucial for 
therapeutic decision in lung cancer. The WHO 
classification of non-small cell lung cancer;  
a proper diagnosis based on immunohistochemistry 
SCC: squamous cell carcinoma; LCC: large cell 
carcinoma; NOS: non-otherwise specified
Immunohistochimemistry Diagnosis
TTF1 p40 CK 5/6 Surgical biopsy 
resection
Small biopsy, 
cytology
+ ± ± Adenocarci-
noma
NSCLC	favour	
adenocarcinoma
– +	(diffuse) SCC NSCLC	favour	
SCC
– +	(focaly,		
<10%	of	cells)
LCC	unclear NOS
– – – LCC	null NOS
no	
stains	
availa-
ble
no	
stains	
availa-
ble
no	
stains	
availa-
ble
LCC	with		
no	additional	
stains
NOS		
(no	stains		
available)
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Figure 1.	First	and	second	line	treatment	regiments	proposal	in	advanced	non-small	cell	 lung	cancer:	a	place	for	immunotherapy	with	immune	
checkpoints	inhibitors	(presented	by	Cardanel	J,	Congres	de	Pneumologie	de	Langue	Francaise,	2018).	IKT:	tyrosine	kinase	inhibitors,	PD-L1:	pro-
grammed	death	ligand	1
non squamous-  
bevacizumab
NIVOLUMAB/?/ 
I line ł II line 
Molecular profile, PD-L1
PL L1 ł 50%
 Oncogenic 
addiction
Other
Squamous cell 
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PD-L1ł 1% PD-L1/?/
  PEMBROLIZUMAB IKT
Chemotherapy 
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± bevacizumab
NIVOLUMAB PEMBROLIZUMAB 
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 Histology
cells (more than 1% of tumor cells). Pembrolizu-
mab is used at a constant dose of 200 mg every 
3 weeks. The recommended dosage of nivolumab 
is 3mg/kg, IV, every 3 weeks. Atezolizumab is 
anti PD-L1 antibody,administered 1200 mg, IV, 
every 3 weeks [4, 12]. Recently the first reports 
from after-trial observations of the use of ICIs in 
clinical practice have been made available. 
Dudnik et al. [13] present their study conduc-
ted in Israel among 342 consecutive patients with 
advanced lung cancer (stage IV), also those in 
poor performance status, treated with nivolumab. 
A median follow-up was 18.5 months. Unfor-
tunately, 60% of the subjects died. The median 
OS was 5.9 months. Of all parameters analyzed: 
age, sex, smoking history, tumor histology, brain 
metastases, previous treatment, only performance 
status (PS) has been shown to have influence on 
response to the treatment. In the patients with 
ECOG PS 0–1, the median OS achieved was 9.5, 
vs. the patients with PS ≥ 2, in whom median 
OS was 3.5 months. The treatment was safe, 1–2 
grade pneumonitis was found in 3 patients, and 
grade 3–4 in 1 patient. The authors concluded 
that in reality, the effectiveness of nivolumab was 
less prominent than in the clinical trials. The OS 
was related to the patient status: the better the PS 
the longer the OS (real life). CLINIVO was a mul-
ticentre French study. The goal of CLINIVO was 
to evaluate the results of nivolumab treatment 
in a real-life setting [14]. 900 patients with stage 
IIIB/IV cancer were included and observed with 
a median follow-up of 26.1 months. The results 
were comparable with those achieved in the 
clinical trials. The median OS was 10 months, 
adverse events were observed in 12% of pa-
tients. Also in this study, there were patients 
with 24-month survival. The presence of brain 
and liver metastases and poor PS were shown 
to be significant unfavorable agents of response 
to nivolumab. The other study was CheckMate 
153, the first randomized study to evaluate tre-
atment duration with a PD-1/PD-L1 inhibitor 
presented by D.R. Spigel on Congress European 
Society for Medical Oncology (ESMO) 2017.The 
prevalence of continuation of treatment after 1 y 
vs. discontinuation and retreatment was noted 
by the authors. Individual 2-year survival was 
achieved in some patients. In Italian observation 
presented by F. Grossi on ESMO Congress 2017, 
an expanded access program of 1588 patients 
in nivolumab treatment was evaluated. The 
median OS was 11 months, 48% of patients 
survived one year, about 40% — 18 months. The 
safety of nivolumab was confirmed, pneumoni-
tis was observed in 1–2% of the treated. A stu-
dy currently conducted in France includes 10 
000 patients with advanced NSCLC qualified 
to second line setting treatment with ICIs. To 
date the mean OS was 8 months, 39% of the 
treated survived 6 months, 12% — 12 months 
[14]. It was presented in many studies and in 
some subgroups of clinical trials that patients 
with oncological addiction (EGFR mutations, 
ALK, ROS1 rearrangements) benefit little from 
PD-1, PD-L1 blockers therapy [9, 15]. KRAS mu-
tation and mutation in 14 exon of MET gene are 
connected with a response to ICIs treatment in 
observation of single patients [16]. 
To summarize, real-life observations present 
that ICIs in lung cancer are efficient to a similar 
extend as in trials, and the answer is highly in-
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dividual. In these observations patients age, sex, 
presence of brain metastases, tumor histology 
and smoking history have not impacted treatment 
efficacy. In qualification to ICIs therapy, the pa-
tient’s PS should be included.
Safety
As checkpoint blockade activates the immune 
system, the adverse events (AEs) related with di-
sordered immunity could be expected. These are 
so- called ”immune-related AEs“ (ir AEs). Their 
pathomechanism is connected with autoimmu-
nity. Interestingly, only some selected organs are 
affected, independently of the type of primary 
tumor. The mostly affected organs are as follows: 
gastrointestinal tract, thyroid, lung, skin, liver 
with the signs of: thyroiditis, colitis, pneumonitis, 
brain inflammation [17, 18]. The irAEs are ob-
served in patients treated with anti CTLA-4 as well 
as with anti PD-1 blockers, but pneumonitis and 
thyroiditis are more common in the latter group. 
For PD-L1 blockers, similar autoimmune disorders 
are observed as for PD-1 inhibitors. The incidence 
of irAEs in patients receiving PD-1, PD-L1 blockers 
was 10 to 16%. The mechanism of immune AEs is 
not fully understood, it is rather connected with 
autoantibodies than with a  cellular response. 
The reasons for an individual tendency to im-
mune-related AEs are unknown; the role of the 
host’s microbiota is taken into account. Real-life 
observations show that a pre-existing nonactive 
autoimmune disease is not a risk factor for irAEs. 
In a recently presented report of three cases with 
idiopathic pulmonary fibrosis (IPF) treated with 
nivolumab, nonworsening was observed [19].
IrAE severity is graded from 1 to 5 (the most 
severe). Immunosuppression with glucocorticoids 
was shown to be effective in treatment of irAEs. 
IrAEs occur early, even after the first doses of 
medication. The risk of AEs does not cumulate 
with doses of blockers or prolonged treatment. 
Thus, in an individual patient, a therapy may be 
continued for years. To date there are no data that 
the AEs are related to the efficacy of checkpoint 
blockers [18]. According to a  recent statement 
of the American Society of Clinical Oncology 
(ASCO), it is recommended to:
— in the case of grade 1 irAEs: the continuation 
of immunotherapy with careful monitoring,
— in grade 2 irAEs: an initial dose of prednisone 
0.5 or 1 mg/kg/d.,
— for grade 3: prednisone in the dose of 1–2 mg/
kg/d. or methylprednisolone IV or, if no im-
provement — infliximab; if after the therapy 
symptoms of irAEs revert to 1 grade, the ICIs 
treatment may be continued’,
— for grade 4 irAEs: the discontinuation of 
immunotherapy [17]. 
Education about an early recognition of 
irAEs is the key to successful treatment. It is po-
inted out that the patients, their family, nurses, 
pharmacists, frontline physicians, all should be 
committed to a proper diagnosis of irAEs [17]. 
There are online projects enabling the reporting of 
all irAEs to the dedicated databases, e.g., the one 
run by the European Respiratory Society (ERS).
Pneumonitis is a special kind of irAE needing 
caution in the case of lung cancer ICIs therapy. 
This non-infectious immune disorder resembling 
interstitial lung disease may be serious. Almost all 
kinds of features of interstitial lung diseases (ILD) 
were described in the CT scans of patients with 
past ICIs pneumonitis [20]. The new changes on 
a chest X-ray or CT scan in the patient treated with 
PD-1, PD-L1 blockers need special attention. The 
following reasons for these changes are possible: 
progression of the disease, infection, pneumonia, 
radiation effects if the patient was previously 
treated with an rtg therapy, and pneumonitis. 
The incidence of pneumonitis is relatively low 
(2.7% in metaanalysis of 20 studies (17) but 
may be serious. In the Keynote 001 study with 
pembrolizumab 2-10 mg/kg IV, pneumonitis was 
observed in 3.8% of the patients, in half of them 
in grade 3–5 [21]. In the OAK study with atezoli-
zumab, pneumonitis was noted in 1% of patients 
[22]. In French real-life studies, pneumonitis was 
not frequent, i.e., 1–2%. A higher incidence of 
this complication was described in a combined 
therapy: nivolumab + ipilimumab.
How to select patients for ICIs?
What about biomarkers? To date, the only 
predictive factor for the ICIs therapy seems to 
be a proportion of cancer cells with the detected 
expression of PD-L1. For pembrolizumab, the OS 
was found to be longer when the tumor proportion 
score (TPS), i.e., the proportion of PD-L1 positive 
cancer cells was high. The higher the proportion 
of PD-L1 positive cells the better the median 
survival. For nivolumab and atezolizumab, the 
collected data were less convincing. In clinical 
trials, different immunohistochemistry (IHC) 
tests for evaluation of PD-L1 expression were 
used showing conflicting results. Thus, currently, 
the efforts are made to find the most accurate 
antibody anti PD-L1 for IHC, the best detection 
system, digitalized methods of cell counting and 
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well-trained staff [21, 23]. Some studies are con-
ducted to develop a proper assessment scheme. 
In practice, PD-L1 expression should be evaluated 
when a pembrolizumab treatment is planned. It 
is recommended to use only histological paraffin- 
embedded samples from a large tumor biopsy, me-
tastases or archival material; cytological material 
is not acceptable [9]. The main reason for pitfalls 
is the cancer tissue heterogeneity. For certain 
quantitative evaluation of PD-L1 expression, the 
availability of a  large fragment of cancer tissue 
is required. Whereas in practice, the resection 
rate in NSCLC is below 25%, the immunothera-
py is restricted to the advanced stages of cancer 
and the tendency to less invasive procedures, as 
a small needle biopsy in lung cancer diagnosing 
dominates. It causes the lack of good quality 
samples for tumor tissue characteristic. The same 
remark concerns the examination of inflammatory 
infiltration in TME, especially tumor infiltrating 
lymphocytes (TIL). There is evidence that evalu-
ation of the character of immune response in the 
cancer site, the so-called ”immunoscore” [24, 25], 
may be crucial for the proper patients selection 
and prediction of irAEs, especially in the lung. We 
have presented in many studies the role of analy-
sis of bronchoalveolar lavage fluid from the lung 
affected by cancer in assessing local immunity 
[25–29]. What is more, the lungs are extremely 
affected by harmful factors like tobacco smoke, 
pollutants, aging, other chronic diseases (COPD, 
ILD), treatment (antibiotics, immunosuppressive 
agents, previous anticancer treatment, hypoxia, 
microbiota). The influence of all the above agents 
may be detected in BALF. 
Apart from individual patients’ features and 
the character of cancer, the resistance to ICIs may 
cause a treatment failure [30]. The issue of PD-1/
PD-L1 blockers is the inhibition of the negative 
regulatory function of PD-1/PD-L1 pathways 
resulting in restoring the primary antitumor im-
mune response. This response to ICIs is highly 
individual; beside those with good results of 
treatment, there are patients who do not respond 
to the initial therapy, who partly respond or who 
acquire resistance to ICIs. The understanding 
of the mechanisms of this primary or acquired 
resistance is important in the context of finding 
biomarkers for immunotherapy. If we want to 
restore the anticancer function of the immune 
system, the latter should work properly. For the 
success of ICIs therapy, an appropriate population 
of T cytotoxic cells is required. The presence of 
CD8+ lymphocytes (cytotoxic T lymphocytes, 
CTLs) was found to be a predictive factor in im-
munotherapy in many studies [10, 30]. Resistance 
to ICIs may be caused by insufficient activity 
of CTLs or disrupted antigen presenting cells 
function. The deletion of CTLs in malignancy is 
observed and is a common reason for resistance 
to ICIs. The other mechanism is the lack of PD-1 
stimulators, like INF-y. Tumors with molecular 
alterations: EGFR mutation, ALK rearrangements 
are found to be resistant to ICIs. Finally, many 
mechanisms of immunosuppression and regula-
tion work together in TME, the PD-1/PD-L1 axis is 
not isolated. Regulatory T cells, myeloid derived 
suppressor cells (MDSCs), regulatory B cells, M2, 
immunosuppressory cytokines and suppressory 
molecules on T cells contribute to silencing the 
immune reaction in TME [6, 7]. 
In the studies of the role of immunoscoring 
in providing the answer to ICIs, the division of 
the tumors to “hot“ and “cold“became accepted. 
The “hot” tumors represent those with the best 
response to ICIs (Fig. 2) [31]. These are tumors 
with high mutation burden (TMB) , releasing new 
neoantigens and more susceptible to ICIs than 
the more stable cancers (among others observed 
in smokers). Improved high-throughput techno-
logies are providing feasible tools for analyzing 
the mutation antigen profile, the gene signature 
and epigenetic modification of tumor and immune 
cells, the breadth of antibody responses, as well 
as the magnitude, homing capacity, cytotoxic 
function and T cell receptor (TCR) repertoire 
of T lymphocytes. The following novel tech-
nologies are incorporated into research: whole 
Figure 2.	Types	of	tumor	microenvironment	in	the	context	of	efficacy	
of	 immunotherapy	 with	 immune	 checkpoint	 inhibitors;	 TIL:	 tumor	
infiltrating	lymphocytes;	INF:	interferon
GOOD RESPONSE POOR RESPONSE 
POOR, UNKNOWN RESPONSE 
PD-L1+TI L+ 
INF-g+ 
NEOANTIGENS 
INFLAMMED 
HOT TUMOR
PD-L1– TIL–
COLD TUMOR
PD-L1+ 
TIL-PD-L1–TIL+
 TOLERANCE 
(other suppresors) 
ONCOGENIC PATHWAYS 
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Table 2.  Activating and suppressory molecules on a T lym-
phocyte and its ligands on a cancer cell — possi-
ble targets for immunotherapy in lung cancer
Immune Checkpoint receptors
Tumor cell Tcell Function
ICOS-L		
MHCclass1/11		
OX-40L		
GITR-L		
CD80		
CD86
ICOS		
KIRs		
OX-40	
GITR		
CD28		
CD28
Activation
CD80	
CD86	
PD-L1	
PD-L2	
Gal-9	
VHEM
CTLA-4	
CTLA-4	
PD-1	
PD-1	
TIM-3	
BTLA	
VISTA
Inhibition
exome sequencing for neoantigens discovery, 
gene signature and pattern, epigenetic-differen-
tiation-based immune cell quantification, protein 
microarray (seromics), T and B cell receptor deep 
sequencing [32].
Perspectives
There is a growing body of evidence that clas-
sical therapies such as chemotherapy, radiothe-
rapy, stereotactic ablative therapy are capable 
of improving the results of ICIs [34]. Combined 
regiments are widely investigated [9, 33]. The pro-
mising results of combined therapy of nivolumab 
with CTLA-4 antibody-ipilimumab have been 
shown [35]. In the near future immunotherapy may 
be helpful in an early stage of disease; III phase of 
clinical trial with anti- PDL1 antibody-durvalumab 
is ongoing [9]. Finally, there are much more pa-
thways beyond PD-1/PD-L1 in cancer, which are 
possible targets for modification (Tab. II) [36]. The 
treatment of lung cancer has entered a new era. 
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